接受阿伐可泮与标准泼尼松减量方案治疗的抗中性粒细胞胞质抗体相关性血管炎患者糖皮质激素毒性指数各领域评分:ADVOCATE试验的事后分析
ADVOCATE试验的事后分析比较阿伐可泮与标准泼尼松减量方案在ANCA相关性血管炎患者中糖皮质激素毒性指数(GTI)各领域的变化。共307例患者纳入分析,阿伐可泮组26周平均糖皮质激素用量低于泼尼松组(1073 mg vs 3192 mg)。第13周时阿伐可泮组在BMI、糖耐量、脂质代谢和皮肤毒性四个领域的糖皮质激素毒性显著低于泼尼松组,第26周时BMI、脂质代谢和皮肤毒性领域的累积恶化评分显著更低;无任何领域显示泼尼松组毒性降低更优。
要点
- 阿伐可泮组26周平均糖皮质激素用量1073 mg,低于泼尼松组的3192 mg。
- 第13周阿伐可泮组BMI、糖耐量、脂质代谢和皮肤毒性领域的累积恶化评分和总体改善评分均显著低于泼尼松组。
- 第26周阿伐可泮组BMI、脂质代谢和皮肤毒性领域的累积恶化评分显著低于泼尼松组,无领域显示泼尼松组更优。
核心结论
- 在ANCA相关性血管炎患者中,以阿伐可泮替代标准泼尼松减量方案可降低多个GTI领域的糖皮质激素毒性。
- 对个体患者而言,糖皮质激素毒性常表现复杂,某些领域改善而另一些领域恶化,突显了直接量化累积恶化和总体变化的复合指标的价值。
研究设计与样本
- ADVOCATE试验是一项3期、双盲、双模拟、随机试验,比较口服阿伐可泮30 mg每日两次共52周联合泼尼松匹配安慰剂20周,与口服泼尼松20周内减量联合阿伐可泮匹配安慰剂52周。
- 本分析为ADVOCATE数据的事后分析,在基线、第13周和第26周收集GTI各领域数据,计算累积恶化评分(CWS)和总体改善评分(AIS),采用Mantel-Haenszel χ2检验比较两组领域评分差异。
- 意向治疗人群330例中,第13周有321例(97%)数据完整(阿伐可泮组160例,泼尼松组161例),第26周有307例(93%)数据完整(阿伐可泮组154例,泼尼松组153例)并纳入本事后分析。
主要发现
- ADVOCATE试验中两组平均年龄均为61岁(阿伐可泮组61.2岁[SD 14.6],泼尼松组60.5岁[14.5]);阿伐可泮组166例中男性98例(59%)、女性68例(41%),泼尼松组164例中男性88例(54%)、女性76例(46%);330例中278例(84%)为白人。
- 26周平均糖皮质激素用量阿伐可泮组低于泼尼松组(1073 mg [SD 1669] vs 3192 mg [1174])。
- 第13周时,基于CWS和AIS,阿伐可泮组在BMI、糖耐量、脂质代谢和皮肤毒性四个GTI领域的糖皮质激素毒性显著低于泼尼松组。
- 第26周时,阿伐可泮组BMI、脂质代谢和皮肤毒性领域的CWS显著低于泼尼松组;无任何领域显示泼尼松组糖皮质激素毒性降低更优。
- 307例中280例(91%)在第26周存在糖皮质激素毒性;第26周CWS权重贡献最大的领域为血压(阿伐可泮组35% vs 泼尼松组25%)、感染(22% vs 24%)和脂质代谢(20% vs 15%);307例中128例(42%)在第26周不同领域同时存在改善和恶化。
关键数值与推荐
- 第26周平均糖皮质激素用量:阿伐可泮组1073 mg(SD 1669)vs 泼尼松组3192 mg(SD 1174)。
- 第26周CWS权重贡献:血压阿伐可泮组35% vs 泼尼松组25%,感染22% vs 24%,脂质代谢20% vs 15%。
- 第26周307例中280例(91%)存在糖皮质激素毒性,128例(42%)在不同领域同时存在改善和恶化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ADVOCATE trial, in which the complement C5a receptor inhibitor avacopan was compared with a standard prednisone taper in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, used the Glucocorticoid Toxicity Index (GTI) to measure glucocorticoid toxicity change. We set out to do a post-hoc analysis of the ADVOCATE data to evaluate changes in individual GTI domains and their ability to differentiate treatment groups. METHODS: The ADVOCATE trial was a phase 3, double-blind, double-dummy, randomised trial comparing oral avacopan (30 mg) twice daily for 52 weeks plus a prednisone-matching placebo for 20 weeks with oral prednisone tapered over 20 weeks plus an avacopan-matching placebo for 52 weeks in patients with ANCA-associated vasculitis. GTI data were collected within each of the included domains (BMI, blood pressure, glucose tolerance, lipid metabolism, glucocorticoid myopathy, skin toxicity, neuropsychiatric effects, and infections) at baseline, 13 weeks, and 26 weeks. In this post-hoc analysis, we calculated the cumulative worsening score (CWS) and aggregate improvement score (AIS) for each GTI domain, assessed to what extend each domain contributed to the GTI score, and which domains differentiated between the avacopan and prednisone groups. Differences in domain scores between the two groups were compared using Mantel-Haenszel χ2 tests. FINDINGS: Among the 330 patients included in the intention-to-treat population of the ADVOCATE trial, 321 (97%) had complete data at week 13 (160 in the avacopan group, and 161 in the prednisone group), and 307 (93%) had complete data at week 26 (154 in the avacopan group, and 153 in the prednisone group) and were assessed in this post-hoc study. In ADVOCATE, mean age in both groups was 61 years (61·2 years [SD 14·6] in the avacopan group; 60·5 years [14·5] in the prednisone group); 98 (59%) of 166 patients in the avacopan group were men and 68 (41%) were women; 88 (54%) of 164 patients in the prednisone group were men and 76 (46%) were women. 278 (84%) of 330 patients were White. The mean glucocorticoid use over 26 weeks was lower in the avacopan group than the prednisone group (1073 mg [SD 1669] vs 3192 mg [1174]). Significantly less glucocorticoid toxicity was observed in the avacopan group than the prednisone group by week 13 in four domains of the GTI (BMI, glucose tolerance, lipid metabolism, and skin toxicity), based on both the CWS and AIS. CWS values in the BMI, lipid metabolism, and skin toxicity domains were significantly lower in the avacopan group than the prednisone group at 26 weeks. No domain favoured the prednisone group for glucocorticoid toxicity reduction. 280 (91%) of 307 patients had glucocorticoid toxicity at 26 weeks. Blood pressure (35% in the avacopan group vs 25% in the prednisone group), infection (22% vs 24%), and lipid metabolism (20% vs 15%) contributed the most weight toward CWS values at 26 weeks. 128 (42%) of 307 patients had combinations of improvement and worsening in different domains at 26 weeks. INTERPRETATION: Replacing a standard prednisone taper with avacopan in patients with ANCA-associated vasculitis reduced glucocorticoid toxicity in multiple GTI domains. For individual patients, glucocorticoid toxicity was often nuanced, improving in some domains while worsening in others. These findings emphasise the value of a composite measure of glucocorticoid toxicity that quantifies cumulative worsening and aggregate change directly. FUNDING: ChemoCentryx.
引用
- Patel NJ, Jayne DRW, Merkel PA, et al. Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol. 2023. PMID: 38251609. doi:10.1016/S2665-9913(23)00030-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。